Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains.
The ageing of the baby-boom generation, combined with new and emerging treatments for neurodegenerative disorders - including multiple sclerosis, Alzheimer's disease and Parkinson's disease - will lead to further expansion of the neurodegenerative therapies market. Increasing disease prevalence and a robust pipeline make that sector dynamic and highly promising for pharmaceutical and biotechnology companies worldwide. Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains why, revealing where the most-exciting developments will lie from the present onwards.
This report examines markets for treating the following disorders in particular:
• Parkinson's disease
• Alzheimer's disease
• Multiple sclerosis
• Amyotrophic lateral sclerosis
• Neuropathies.
Also covered are the following neurodegenerative disorders:
• Huntington’s disease
• Prion diseases.
What types of therapeutic agent are likely to enter the market from 2009 onwards, and will they hold the potential to dominate this market area? Where will the best commercial opportunities lie from 2009 onwards? What are the most-crucial drivers and restraints in this market? This report will provide you with the information that you need to understand current trends and future directions in neurodegenerative disorder therapies.
In particular, we discuss prospects for the following products in detail:
• Sifrol
• Stalevo
• Requip
• Aricept
• Namenda
• Exelon
• Reminyl
• Avonex
• Copaxone
• Rebif
• Betaferon
• Rilutek.
In our pipeline analyses we include emerging therapeutics such as stem cells, gene therapy and monoclonal antibodies, among other prominent developments.
Detailed analysis of the neurodegenerative disorders market sector
World Neurodegenerative Diseases Market 2009-2024 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 63 tables and figures included, as well as three full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Research interviews from our comprehensive survey
This report contains interviews with the following relevant experts:
1) Dr Johan Luthman, former Global Head of Exploratory Medicine (Neurology, Autoimmune & Inflammatory Diseases), Merck Serono
2) Dr Allan Tobin, Senior Scientific Advisor to the CHDI Foundation
3) Professor Peter Jenner, founder and Chief Science Officer, Proximagen Neurosciences, and Professor in Pharmacology, King's College, University of London.
Why you should buy World Neurodegenerative Diseases Market 2009-2024
In this report you will receive the following benefits in particular:
• You will assess the current market for neurodegenerative disease therapeutics
• You will review the overall neurodegenerative disease therapeutics market, including a global sales forecast for 2009 to 2024
• You will receive sales forecasts for neurodegenerative disorder submarkets from 2009 to 2024, with detailed discussions
• You will receive sales forecasts for leading products from 2009 to 2024, with detailed discussions of market potential and competition
• You will receive sales forecasts for leading geographical markets from 2009 to 2024, with informed discussion
• You will examine commercial drivers and restraints in depth
• You will discover the most-exciting pipeline developments in the sector, with informed commentary
• You will discover expert opinions from our original survey of the sector, with prominent contributions from industry and academia.
You can obtain this report today
Nobody with an interest in the neurodegenerative diseases sector can afford to overlook this new market study. We predict that total revenues will increase throughout our forecast period, 2009 to 2024. With rising disease prevalence and expanding patient populations - coupled with high economic and social costs of those diseases - this therapeutic area holds significant potential for revenue growth. Do you want to harness those opportunities? You can stay ahead by ordering this report today.
Global Pharmaceutical Industry
Table of Contents
1. Executive Summary
1.1 Aims of this Report
1.2 Chapter Breakdown
2. Neurodegenerative Diseases: An Introduction
2.1 What Are Neurodegenerative Diseases?
2.2 Prevalence and Economic Impact
2.3 Types of Neurodegenerative Diseases
2.3.1 Parkinson's Disease
2.3.2 Alzheimer's Disease
2.3.3 Multiple Sclerosis
2.3.4 Huntington's Disease
2.3.5 Amyotrophic Lateral Sclerosis
2.3.6 Neuropathies
2.3.7 Prion Diseases
3. Neurodegenerative Diseases, Global Market 2009-2024
3.1 Analysis of the Current Market
3.2 Neurodegenerative Diseases, Forecast 2009-2024
3.3 Symptomatic Treatment
3.4 Multiple Sclerosis at the Forefront of the Market
3.5 Future Directions
4. Parkinson's Disease
4.1 Prevalence and Economic Impact
4.2 Current Treatment Options
4.3 Parkinson's Disease Market Forecast 2009-2024
4.4 Sifrol Forecast 2009-2024
4.4.1 Patent Expiries
4.5 Stalevo Forecast 2009-2024
4.5.1 Patent Expiries and Generic Challenges
4.5.2 The FIRST STEP trial
4.6 ReQuip Forecast 2009-2024
4.6.1 Patents and Lifecycle Management
4.7 Concluding Remarks
5. Alzheimer's Disease
5.1 Prevalence and Economic Impact
5.2 Treatment Options
5.3 Analysis of the Current Market
5.4 Alzheimer's Disease Market Forecast 2009-2024
5.5 Aricept Forecast 2009-2024
5.5.1 Patents
5.6 Namenda Forecast 2009-2024
5.6.1 Patents and Generic Challenges
5.7 Exelon Forecast 2009-2024
5.7.1 Patent Expiries
5.8 Reminyl Forecast 2009-2024
5.8.1 Generic Challenges
5.9 Future Directions and Concluding Remarks
6. Multiple Sclerosis
6.1 Economic and Social Impact
6.1.1 Prevalence
6.2 Treatment Options
6.2.1 Treatment for Relapses
6.2.2 Treatment for Symptoms
6.2.3 Disease-Modifying Medicines
6.3 Analysis of the Current Market
6.4 Multiple Sclerosis Market Forecast 2009-2024
6.5 Avonex Forecast 2009-2024
6.5.1 Markets and Patent Expiries
6.5.2 Strong Competition Will Erode Market Share
6.6 Copaxone Forecast 2009-2024
6.6.1 A Unique Therapy - For Now
6.6.2 Forthcoming Patent Expiries
6.7 Rebif Forecast 2009-2024
6.7.1 New Delivery Mechanism to Improve Sales
6.7.2 Efficacy Studies
6.8 Betaferon Forecast 2009-2024
6.8.1 Patent Expiries
6.8.2 Strong Competition
6.9 Future Directions
6.9.1 The Re-Launch of Tysabri
7. Amyotrophic Lateral Sclerosis
7.1 Possible Causes of ALS
7.2 Prevalence
7.3 Treatment Options
7.4 Analysis of the Current Market
7.5 Amyotrophic Lateral Sclerosis Market Forecast 2009-2024
7.6 Rilutek Forecast 2009-2024
7.6.1 New Indications
7.6.2 Patents
7.7 Future Directions
7.7.1 Insmed's Iplex
8. Neuropathies
8.1 Treating the Underlying Cause
8.2 Surgery and Physical Therapy
8.3 Pharmacological Treatments
8.3.1 Aldose Reductase Inhibitors
8.3.2 Antidepressants
8.3.3 Analgesics
8.3.4 Anticonvulsants
8.4 Analysis of the Current Market
8.4.1 Economic and Social Impact
8.4.2 Increasing Prevalence and Treatment Strategies
8.5 Neuropathies Market Forecast 2009-2024
8.6 Kinedak Forecast 2009-2024
8.6.1 Adverse Effects and Safety Warnings
8.6.2 Direct Competition in the Pipeline
8.7 Future Directions
9. Huntington's Disease
9.1 Prevalence and Economic Impact
9.2 Treatment Options
9.2.1 Monoamine-Depleting Agents
9.2.2 Benzodiazepines
9.2.3 Dopamine Antagonists
9.3 Analysis of the Current Market and Future Directions
10. Prion Diseases
10.1 Creuztfeldt-Jacob Disease
10.2 Gerstmann-Straussler-Scheinker Disease
10.3 Kuru
10.4 Fatal Familial Insomnia
10.5 Prevalence
10.6 Analysis of the Current Market
10.6.1 Increasing Prevalence Could Alter the Market
11. Geographical Breakdown of the Market
11.1 USA
11.2 Europe
11.3 Emerging Markets
11.3.1 China versus India
11.3.2 Brazil
11.4 Concluding Remarks
12. Future Directions
12.1 Stem Cell Therapy for Neurodegenerative Diseases
12.2 Cybrids: "Disease in a Dish" Models
12.3 Gene Therapy: Promising Results
12.4 Hopes for Alzheimer's Treatment
12.4.1 Monoclonal Antibody Bapineuzumab (AAB-001)
12.4.2 Monoclonal Antibody Solanezumab
12.5 The MS Pipeline
12.5.1 Monoclonal Antibodies for the Treatment of MS
12.5.2 Managing Immune Activity
12.5.3 Statins: A Further Role?
12.5.4 Concluding Remarks on the MS Pipeline
12.6 Huntington's Disease: Future Developments
12.6.1 Dimebon
12.6.2 Cystamine
12.6.3 HDAC Inhibitors
12.6.4 RNAi as a Potential Treatment
12.6.5 The Case for Brain-Derived Neurotrophic Factor (BDNF)
12.6.6 What About Stem Cells and Gene Therapy?
12.7 ALS: The Pipeline
12.7.1 Knopp Neurosciences' KNS-760704
12.7.2 CytRx Corporation's Arimoclomol
13. Drivers and Restraints
13.1 Drivers in the Market
13.1.1 The Ageing Population and Increasing Prevalence
13.1.2 The MS Market: Oral Products May Expand Revenues
13.1.3 Advances in Research
13.1.4 Chronic Diseases: Long-Term Repeat Sales
13.1.5 Unmet Needs in the Patient Population
13.2 Restraints in the Market
13.2.1 High Product Competition
13.2.2 The High Cost of Treatment
13.2.3 The MS Market: Patient Compliance
13.2.4 Patent Expiries and Generic Competition
13.3 Concluding Remarks
14. Expert Opinions
14.1 Interview with Dr Johan Luthman
14.1.1 On Understanding the Disease and its Treatments
14.1.2 On Unmet Needs for Treatments
14.1.3 On Current Treatment Options
14.1.4 On Future Treatment Possibilities
14.1.5 On Stem Cell Media Coverage
14.1.6 On the Therapeutic and Curative Potential of Stem Cells for Neurological Diseases
14.1.7 On the Treatment of Neurological Diseases
14.1.8 On the Time Frame for Marketable Stem Cell Treatment Options
14.2 Interview with Dr Allan Tobin (CHDI Foundation)
14.2.1 On the Possibility of a Cure
14.2.2 On the Pipeline for Huntington's Disease
14.2.3 On the Advantages and Disadvantages of Studying Huntington's Disease
14.2.4 On the Market Value of a Treatment for Huntington's Disease
14.3 Interview with Professor Peter Jenner (Proximagen Neurosciences and King’s College, University of London)
14.3.1 On the Challenges in the Treatment of Parkinson’s Disease
14.3.2 On Promising Therapeutics
14.3.3 On the Possibility of a Cure
14.3.4 On Stem Cells in the Treatment of Parkinson’s Disease
14.3.5 On Important Areas of Research
15. Conclusions
15.1 Multiple Sclerosis Treatments Lead the Market Area
15.2 Chronic Conditions and Treatment Options
15.3 Comments on the Global Market
15.4 Potential in the Pipeline
15.5 Geographical Opportunities
List of Tables
Table 2.1 Types of Neurodegenerative Diseases
Table 3.1 Neurodegenerative Diseases Market: World Sales ($m), 2008-2014, 2019 and 2024
Table 4.1 Parkinson's Disease Symptoms
Table 4.2 Key Anti-Parkinson Drugs, World Sales ($m) and Market Share (%), 2008
Table 4.3 Anti-Parkinson's Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 5.1 FDA Approved Alzheimer's Therapeutics, 2009
Table 5.2 Key Anti-Alzheimer's Drugs, World Sales ($m) and Market Share (%), 2008
Table 5.3 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 6.1 Multiple Sclerosis: Possible Risk Factors
Table 6.2 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 6.3 Leading MS Drugs, World Market Share (%), 2008, 2014, 2019 and 2024
Table 7.1 Factors Associated With the Onset of ALS
Table 7.2 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 8.1 Apparent Causes for Neuropathy
Table 8.2 Top-Selling Local Anaesthetics ($m), 2008
Table 8.3 Key Therapeutics Indicated for Neuropathies, 2009
Table 8.4 Neuropathies Therapeutics World Sales ($m), 2008-2014, 2019 and 2024
Table 9.1 Treatment Options for Huntington's Disease, 2009
Table 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
Table 11.1 The Neurodegenerative Market by Country, Sales ($m), CAGR (%) and Market Share (%), 2008-2014, 2019 and 2024
Table 12.1 Number of Pipeline Products by Phase and Disease, 2009
Table 12.2 Key Products in the MS Pipeline, 2009
Table 13.1 SWOT Analysis for Neurodegenerative Diseases, 2009
List of Figures
Figure 3.1 The Neurodegenerative Market World Sales ($m), 2008
Figure 3.2 Neurodegenerative Diseases Market World Sales ($m), 2008-2024
Figure 3.3 Neurodegenerative Market by Therapeutic Area, World Sales ($m), 2009, 2014 2019, 2024
Figure 4.1 Anti-Parkinson's Therapeutics World Sales ($m), 2008-2024
Figure 4.2 Anti-Parkinson's Drugs, World Market Share (%), 2008
Figure 4.3 Sifrol World Sales ($m), 2008-2024
Figure 4.4 Stalevo World Sales ($m), 2008-2024
Figure 4.5 ReQuip World Sales ($m), 2008-2024
Figure 5.1 Key Anti-Alzheimer's Drugs, World Market Share (%), 2008
Figure 5.2 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2008-2024
Figure 5.3 Anti-Alzheimer's Disease Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
Figure 5.4 Aricept World Sales ($m), 2008-2024
Figure 5.5 Namenda World Sales ($m), 2008-2024
Figure 5.6 Exelon World Sales ($m), 2008-2024
Figure 5.7 Reminyl World Sales ($m), 2008-2024
Figure 6.1 Multiple Sclerosis Therapeutics World Sales ($m), 2008-2024
Figure 6.2 Key Multiple Sclerosis Therapeutic Products, World Sales ($m), 2008
Figure 6.3 Avonex World Sales ($m), 2008-2024
Figure 6.4 Copaxone World Sales ($m), 2008-2024
Figure 6.5 Rebif World Sales ($m), 2008-2024
Figure 6.6 Betaferon World Sales ($m), 2008-2024
Figure 6.7 Leading MS Drugs, World Market Share (%), 2008
Figure 6.8 Leading MS Drugs, World Market Share (%), 2024
Figure 6.9 Leading MS Drugs, World Sales ($m), 2008, 2014, 2019, 2024
Figure 7.1 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2008-2024
Figure 7.2 Rilutek World Sales ($m), 2008-2024
Figure 7.3 Amyotrophic Lateral Sclerosis Therapeutics World Sales ($m), 2009, 2014, 2019 and 2024
Figure 8.1 Neuropathies Therapeutics World Sales ($m), 2008-2024
Figure 8.2 Neuropathic Pain and General Neuropathic Therapeutics, World Market Share (%), 2008
Figure 8.3 Neuropathic Pain and General Neuropathic Therapeutics, World Sales ($m), 2009, 2014, 2019 and 2024
Figure 8.4 Kinedak World Sales ($m), 2008-2024
Figure 8.5 Kinedak and Other General Neuropathic Products, World Sales ($m), 2008, 2014, 2019 and 2024
Figure 10.1 Number of Suspected CJD and GSS Cases in the UK, 1998-2008
Figure 11.1 The Neurodegenerative Market by Country, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.2 European Neurodegenerative Market, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.3 China, India and Brazil, Sales ($m), 2009, 2014, 2019 and 2024
Figure 11.4 Geographical Breakdown of the World Market, Sales ($m), 2008
Figure 11.5 Geographical Breakdown of the World Market, Sales ($m), 2024
Figure 12.1 Number of Pipeline Products by Phase and Disease, 2009
Figure 12.2 Number of Products in the Alzheimer's Pipeline by Phase, 2009
Companies Listed
Acorda Therapeutics
Active Biotech
Aguettant
AstraZeneca
Bayer
Biogen Idec
BioMS Medical
Boehringer Ingelheim
Cobalt
CHDI Foundation
CytRx Corporation
Dainippon Sumitomo
Dr. Reddy's Laboratories
Eisai
Elan
Eli Lilly
EMD Serono
EMEA
Endo
Forest
GlaxoSmithKline
Hermes
Insmed
InterMune
Johnson & Johnson
Knopp Neurosciences
Lundbeck
Lupin
Medivation
Merck & Co
Merck Serono
Merck KGaA
Momenta Pharmaceuticals
Mylan
Natco
Neuren
Novartis
Ono Pharmaceuticals
Orchid
Orion Corporation
Pfizer
Proximagen Neurosciences
ReceptoPharm
Roche
Roxane
Sanofi-Aventis
Sun Pharmaceuticals
Takeda
Teva
The Alzheimer's Association
The European Medicines Agency
The Human Fertilisation and Embryology Authority
The National Academy of Sciences
The World Health Organisation (WHO)
Upsher-Smith
US Food and Drug Administration (FDA)
Watson Pharmaceuticals
Wockhardt
Wyeth
